Pharmaceutical Technology

APRIL 10, 2023

India-based pharmaceutical company Cipla has entered into a perpetual licence agreement with Swiss drugmaker Novartis Pharma for the diabetes drug Galvus and its combination brands. Under the deal, Cipla will be responsible for the manufacturing and marketing of Galvus and its combination brands from 1 January 2026.

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies 52

STAT

JUNE 6, 2024

… Eli Lilly’s blockbuster diabetes and obesity drug improved liver scarring in a mid-stage study of the liver disease MASH, adding to positive data announced earlier this year, STAT tells us. But the patent on semaglutide, the active ingredient in both drugs, expires in China in 2026. So no need to mess with rebates.

Diabetes 243

Diabetes 243

STAT

AUGUST 22, 2023

Jardiance, a diabetes medicine co-marketed by Boehringer, is expected to be among the first drugs to face negotiation once the law takes effect in 2026. Continue to STAT+ to read the full story…

Vaccines 200

Vaccines Drug Pricing Diabetes Pharmaceutical Companies 200

STAT

SEPTEMBER 18, 2024

  A Novo Nordisk executive believes that Ozempic, the blockbuster diabetes shot made by the company, is “very likely” to be one of the next drugs targeted for a price cut in bargaining with the Medicare program, Bloomberg News writes. The Inflation Reduction Act, which allows the U.S.

Hospitals 223

Hospitals Drug Pricing Diabetes 223

European Pharmaceutical Review

SEPTEMBER 12, 2024

Edgardo Hernandez , Executive Vice President and President of Lilly Manufacturing Operations, explained that the company ’s new investments will enhance production of medicines for diabetes, obesity and Alzheimer’s. Production is expected to begin in 2026.

Diabetes 105

Diabetes 105

pharmaphorum

SEPTEMBER 30, 2022

Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug for another few years. That challenged the ‘708 patent – which expires in November 2026 – as well as one other (No.

Diabetes 59

Diabetes Vaccines 59

European Pharmaceutical Review

AUGUST 22, 2024

Based on their rising popularity to treat type 2 diabetes and obesity, GlobalData has predicted that sales of glucagon-like peptide-1 receptor (GLP-1R) drugs will increase fourfold to an estimated $142 billion by 2030. Eli Lilly shared that production of the medicines will commence at the Lebanon site towards the end of 2026.

Diabetes 59

Diabetes 59

Putting Patients First Blog

JULY 2, 2024

1 And we appreciated CMS’ thorough responses to comments for IPAY 2026 and hope the Agency will replicate this for this comment opportunity. These elements were previously highlighted in our comments in response to the IPAY 2026 guidance, and we continue to stress their importance for the 2027 draft guidance.

Drug Pricing 52

Drug Pricing Insurance Coverage and Processing HIPAA Labelling 52

Pharma Mirror

JANUARY 24, 2023

With the promise of significant breakthroughs in treatment of diabetes, cancer, and congenital conditions, it is no wonder that research and development is predicted to reach $232.5 billion by 2026, up from $186 billion in 2019 according to the Evaluate Pharma report.

Diabetes 52

Diabetes Drug Development 52

European Pharmaceutical Review

MAY 27, 2024

These treatments are indicated for obesity and type 2 diabetes. Eli Lilly anticipates that medicine production at the Lebanon site will begin near the end of 2026. This new $5.3 billion investment tops the largest manufacturing investment in [Eli Lilly’s] history” This new $5.3

Diabetes 105

Diabetes 105

Express Pharma

AUGUST 8, 2024

Benemae Pharmaceutical’s benaglutide injection (Feisumei) was the first innovator approved for obesity in July 2023 in China followed by Novo Nordisk’s diabetes therapy semaglutide (Wegovy) in June 2024. Both are GLP-1 receptor agonists. Tirzepatide’s US patent lasts until 2036, with no known biosimilars, even in China.

Biosimilars 102

Biosimilars Diabetes 102

European Pharmaceutical Review

APRIL 1, 2024

. “ABBV-RGX-314 [could] become a first-in-class gene therapy for wet AMD and the standard of care to treat and prevent progression of diabetic retinopathy,” stated Kenneth Mills, President and Chief Executive Officer of REGENXBIO. Regulatory submissions are expected in late 2025 through the first half of 2026, REGENXBIO confirmed.

Diabetes 98

Diabetes 98

European Pharmaceutical Review

FEBRUARY 5, 2024

Novo Nordisk specified that the transaction is expected to support an incremental increase in the company’s filling capacity from 2026 and onwards. Jørgensen shared that the firm is “very pleased” with the agreement, as it will allow the company to “serve significantly more people living with diabetes and obesity in the future”.

Diabetes 98

Diabetes 98

Pharmaceutical Technology

MAY 9, 2023

Revenue prospects for Novo Nordisk’s blockbuster diabetes and weight-loss drug semaglutide in Brazil have been dealt a major blow after a federal court denied a request by the Danish firm for two patent extensions. Ozempic has been approved for diabetes in Brazil since 2018, joined by Rybelsus in 2020 and Wegovy in January this year.

Diabetes 59

Diabetes Labelling 59

pharmaphorum

APRIL 29, 2022

Soriot also highlighted to performance of Farxiga (dapagliflozin), AZ’s SGLT2 inhibit for diabetes, heart failure and chronic kidney disease, which made $1 billion in the quarter, with a higher-than-predicted rise of 60% over the same period of 2021.

Diabetes 111

Diabetes Vaccines 111

PharmaShots

FEBRUARY 22, 2023

Approved Indications of Trulicity2 Trulicity is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: As an adjunct to diet and exercise to improve glycaemic control in adults and paediatric patients (age: ≥10 years) with type 2 diabetes mellitus. million patients’ journeys with type 2 diabetes since 2014.

Diabetes 64

Diabetes Compounding Dosage Communication 64

Express Pharma

SEPTEMBER 12, 2023

Albutein appears to be on track to be the first therapeutic approved for DC, with a projected US launch date in Q1 2026. As such, it is unsurprising that a stem cell therapy is being considered for the treatment of DC due to NASH. tumor formation, immune reactions, and therapy failure).

Diabetes 111

Diabetes Immunity Immunization 111

pharmaphorum

FEBRUARY 10, 2022

The drug is important to Bayer as Xarelto is coming to the end of its patent life and facing the threat of low-cost generic competition starting in 2026 that will eat into its sales. All three studies are looking at the drug on its own and in combination with anti-platelet therapies like aspirin and clopidogrel.

Diabetes 98

Diabetes 98

pharmaphorum

NOVEMBER 25, 2022

In early 2026, Grünenthal intends to buy out the remaining stake in the JV to claim full control of the products, which include fentanyl-based products Abstral and PecFent for breakthrough cancer pain, Moventig (naloxegol) for opioid-induced constipation, and nutritional supplement Adcal-D3 for osteoporosis. billion in 2021.

Diabetes 52

Diabetes 52

LifeProNow

MARCH 27, 2023

Kerendia is already approved in major markets in chronic kidney disease (CKD) associated with type 2 diabetes. billion in sales by 2026. Bayer has exclusive worldwide marketing rights for this product including the U.S. The medical imaging AI market is the fastest growing segment within the global radiology industry.

Bioethics 130

Bioethics Compounding Diabetes 130

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Biosimilars 52

Biosimilars Labelling Diabetes Compounding 52

Pharma Marketing Network

MAY 12, 2021

Billion by 2026 with a CAGR of 37.2% This year, we are, and will continue to witness patients with chronic health conditions, like diabetes and hypertension, for example, make use of telehealth services. According to a stat by Medgadget, “Global Telemedicine Market is valued at USD 27.04 Billion in 2019 and Expected to Reach USD 171.81

Diabetes 59

Diabetes 59

STAT

JANUARY 30, 2024

Five Wall Street analysts and two investors told Reuters they expect the negotiations over prices that will go into effect in 2026 to result in cuts ranging from the statutory minimum of 25% to as much as 60% when the final numbers are set in September. The drugmakers and the government are expected to wait until then to disclose them.

Diabetes 228

Diabetes Pharmaceutical Companies Pharmaceutical Companies 228

RX Note

FEBRUARY 4, 2024

Prevention in Public Health Pharmacists play a crucial role in primary healthcare, offering services like disease risk assessment, screening, patient referrals, disease management and medication optimization for noncommunicable diseases like cardiovascular conditions, asthma , chronic obstructive pulmonary disease and diabetes mellitus.

Community Pharmacies 52

Community Pharmacies Medical Records Compounding Diabetes 52

Putting Patients First Blog

JANUARY 10, 2024

Pharmacy and Therapeutics (P&T) Committee Standards: The NHC supports the inclusion of a consumer representative in P&T committees starting January 1, 2026, ensuring patient perspectives are considered in formulary decisions, decisions with patient needs and preferences.

Insurance Coverage and Processing 40

Insurance Coverage and Processing Communication Documentation Diabetes 40

Safe Biologics

APRIL 10, 2023

Live panelists included Dr. Stephen James, Director, Division of Digestive Diseases and Nutrition at the National Institute for Diabetes, Digestive and Kidney Diseases and Brenda Rodriguez, Senior Engagement Officer at the Patient-Centered Outcomes Research Institute. This year’s theme was “Improving Patient Care.”

Biosimilars 130

Biosimilars Drug Pricing Diabetes Labelling 130